Scarica l'app Stockscreener
4.18
0.00%
0.00
Dopo l'orario di chiusura:
4.21
0.03
+0.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
Why Altimmune Inc. stock attracts strong analyst attentionHigh Yield Opportunities - beatles.ru
What makes Altimmune Inc. stock price move sharplyFree Risk Assessment Services - Newser
How Altimmune Inc. stock performs during market volatilityFree Premium Stock Market Reports - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.
OneDigital Investment Advisors LLC Sells 2,887 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Concurrent Investment Advisors LLC Purchases New Holdings in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune (NASDAQ:ALT) Upgraded to “Strong Sell” at The Goldman Sachs Group - Defense World
Altimmune (NASDAQ:ALT) Upgraded at The Goldman Sachs Group - Defense World
Pomerantz LLP investigates securities fraud claims in Altimmune's IMPACT Phase 2b trial. - AInvest
The Goldman Sachs Group Upgrades Altimmune (NASDAQ:ALT) to Strong Sell - Defense World
Altimmune (NASDAQ:ALT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World
JMP Securities Lowers Altimmune (NASDAQ:ALT) Price Target to $15.00 - Defense World
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - TipRanks
Altimmune falls after Goldman resumes coverage with "sell", citing competition - TradingView
Citizens JMP lowers Altimmune stock price target to $15 on fibrosis miss - Investing.com Nigeria
Goldman Sachs downgrades Altimmune stock to Sell on pemvidutide concerns - Investing.com Canada
Altimmune Plunges 14.56% on Goldman Sachs Downgrade - AInvest
Altimmune resumed with a Sell at Goldman Sachs - TipRanks
Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development - TipRanks
ATTENTION Altimmune, Inc. (ALT) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
How To Trade (ALT) - news.stocktradersdaily.com
Altimmune enrolls first patient in ALD treatment trial By Investing.com - Investing.com Nigeria
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluati - GuruFocus
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) - The Manila Times
Altimmune, Inc. Enrolls First Patient in RESTORE Phase 2 Trial for Pemvidutide in Alcohol-Associated Liver Disease - Quiver Quantitative
Altimmune enrolls first patient in ALD treatment trial - Investing.com
Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial - Insider Monkey
ALT ALERT: Levi & Korsinsky Investigates Altimmune, Inc. for Possible Securities Fraud Violations - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - WV News
Sequoia Financial Advisors LLC Decreases Position in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Shareholders Alert: Investigation Into Altimmune, Inc. (ALT)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Altimmune, Inc. (ALT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Altimmune’s Unexpected Surge: What’s Behind It? - StocksToTrade
Would you recommend buying alt stock for the July? Do deep analysis and check everything - AInvest
Lost Money on Altimmune, Inc. (ALT)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of an Investigation into Altimmune, Inc. (ALT) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Altimmune plunges after mid-stage trial data for MASH therapy - MSN
Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief - Benzinga
Altimmune (ALT) Reports Promising Phase 2b Results for Pemvidutide | ALT Stock News - GuruFocus
Altimmune (ALT) Shares Drop Despite Positive Phase 2b Trial Results | ALT Stock News - GuruFocus
Altimmune (ALT) Reports Promising Phase 2b Trial Results for Pemvidutide | ALT Stock News - GuruFocus
Altimmune stock falls after MASH treatment trial results By Investing.com - Investing.com India
Altimmune's weight-loss drug meets main goal in fatty liver disease trial - TradingView
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 - Yahoo Finance
Altimmune Shares Soar 3.39% on Positive Diabetes Data - AInvest
Altimmune Announces Multiple Presentations at Upcoming American - GuruFocus
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions - The Manila Times
Breakthrough GLP-1/Glucagon Drug Pemvidutide Reveals Multiple Cardiometabolic Benefits in New Clinical Data - Stock Titan
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions - Yahoo Finance
Kalkine : Altimmune’s Role in NASDAQ Composite Amid Biotech Sector Momentum - Kalkine Media
Altimmune Stock: On the Rise Again? - StocksToTrade
Altimmune, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
Two Sigma Advisers LP Sells 22,700 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Nuveen Asset Management LLC Has $1.56 Million Stock Position in Altimmune, Inc. (NASDAQ:ALT) - Defense World
BNP Paribas Financial Markets Sells 33,984 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Stifel analysts reaffirm Altimmune stock rating with $18 price target By Investing.com - Investing.com South Africa
3.40%
2.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):